Luca Di Lullo, Carlo Lavalle, Michele Magnocavallo, Marco Valerio Mariani, Domenico Giovanni Della Rocca, Paolo Severino, Biagio Raffaele Di Iorio, Domenico Russo, Francesco Summaria, Giovanni Battista Forleo, Claudio Ronco, Massimo Mancone, Cristina Chimenti, Fabio Miraldi, Andrea Natale, Antonio Bellasi
BACKGROUND: Rivaroxaban is a direct inhibitor of activated Factor X (FXa), an anti-inflammatory protein exerting a protective effect on the cardiac valve and vascular endothelium. We compare the effect of Warfarin and Rivaroxaban on inflammation biomarkers and their contribution to heart valve calcification progression and renal preservation in a population of atrial fibrillation (AF) patients with chronic kidney disease (CKD) stage 3b - 4. METHODS: This was an observational, multicenter, prospective study enrolling 347 consecutive CKD stage 3b - 4 patients newly diagnosed with AF: 247 were treated with Rivaroxaban and 100 with Warfarin...
December 15, 2021: International Journal of Cardiology